Literature DB >> 30858768

Management of interruptions in radiotherapy treatments: Adaptive implementation in high workload sites.

Gustavo Pozo1, Maria Angeles Pérez-Escutia2, Ana Ruíz2, Alejandro Ferrando1, Ana Milanés1, Eduardo Cabello1, Raul Díaz1, Alejandro Prado1, Jose Fermin Pérez-Regadera2.   

Abstract

Owing to predictable or unpredictable causes, interruptions may arise during therapy. On average, the extension of fractionated radiotherapy treatments is prone to be delayed by several weeks and interruptions can come up extending overall treatment time (OTT). Clonogenic cells of aggressive tumors might benefit from this situation, modifying local control (LC). Preserving treatment quality in radiotherapy is an essential issue for the treatment outcome, and our institution is increasingly concerned about this line of work. Establishing some objective criteria to schedule patients that have suffered interruptions along their treatments is of capital importance and not a trivial issue. Publications strongly encourage departments to minimize the effect of lag periods during treatments. Therefore, in July 2017, our facility implemented the so called 'Protocol to Manage Interruptions in Radiotherapy', based on a scoring system for patient categorization that considers not only histology but also associated comorbidity and sequence of the therapy.

Entities:  

Keywords:  Dose compensation; OTT; Treatment interruption; Treatment quality; Workload

Year:  2019        PMID: 30858768      PMCID: PMC6395853          DOI: 10.1016/j.rpor.2019.02.003

Source DB:  PubMed          Journal:  Rep Pract Oncol Radiother        ISSN: 1507-1367


  21 in total

Review 1.  Practical methods for compensating for missed treatment days in radiotherapy, with particular reference to head and neck schedules.

Authors:  R G Dale; J H Hendry; B Jones; A G Robertson; C Deehan; J A Sinclair
Journal:  Clin Oncol (R Coll Radiol)       Date:  2002-10       Impact factor: 4.126

2.  Radiotherapy-related early morbidity in head and neck cancer: quantitative clinical radiobiology as deduced from the CHART trial.

Authors:  S M Bentzen; M I Saunders; S Dische; S J Bond
Journal:  Radiother Oncol       Date:  2001-08       Impact factor: 6.280

3.  Compliance to the prescribed overall treatment time (OTT) of curative radiotherapy in normal clinical practice and impact on treatment duration of counteracting short interruptions by treating patients on Saturdays.

Authors:  M Maciá I Garau; J Solé Monné; M J Cambra Serés; C Monfà Binefa; M Peraire Llopis
Journal:  Clin Transl Oncol       Date:  2009-05       Impact factor: 3.405

4.  The management of interruptions to radiotherapy in head and neck cancer: an audit of the effectiveness of national guidelines.

Authors:  N D James; M V Williams; E T Summers; K Jones; B Cottier
Journal:  Clin Oncol (R Coll Radiol)       Date:  2008-06-13       Impact factor: 4.126

5.  Repair halftimes estimated from observations of treatment-related morbidity after CHART or conventional radiotherapy in head and neck cancer.

Authors:  S M Bentzen; M I Saunders; S Dische
Journal:  Radiother Oncol       Date:  1999-12       Impact factor: 6.280

Review 6.  [Delays and treatment interruptions: difficulties in administering radiotherapy in an ideal time-period].

Authors:  Carmen González San Segundo; Felipe A Calvo Manuel; Juan Antonio Santos Miranda
Journal:  Clin Transl Oncol       Date:  2005-03       Impact factor: 3.405

Review 7.  Meta-analysis of the alpha/beta ratio for prostate cancer in the presence of an overall time factor: bad news, good news, or no news?

Authors:  Ivan R Vogelius; Søren M Bentzen
Journal:  Int J Radiat Oncol Biol Phys       Date:  2012-05-30       Impact factor: 7.038

Review 8.  Effects of prolongation of overall treatment time due to unplanned interruptions during radiotherapy of different tumor sites and practical methods for compensation.

Authors:  Nuran Senel Bese; Jolyon Hendry; Branislav Jeremic
Journal:  Int J Radiat Oncol Biol Phys       Date:  2007-04-30       Impact factor: 7.038

9.  How fast is repopulation of tumor cells during the treatment gap?

Authors:  Rafal Tarnawski; Jack Fowler; Krzysztof Skladowski; Andrzej Swierniak; Rafal Suwiński; Boguslaw Maciejewski; Andrzej Wygoda
Journal:  Int J Radiat Oncol Biol Phys       Date:  2002-09-01       Impact factor: 7.038

10.  Prognostic importance of comorbidity in a hospital-based cancer registry.

Authors:  Jay F Piccirillo; Ryan M Tierney; Irene Costas; Lori Grove; Edward L Spitznagel
Journal:  JAMA       Date:  2004-05-26       Impact factor: 56.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.